Amundi
CLDX icon

Amundi’s Celldex Therapeutics CLDX Stock Holding History

Amundi’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Hold
9,351
– – ﹤0.01% 1794
2026
Q1 		$297K Buy
+9,351
New +$255K ﹤0.01% 1745
2025
Q2 		– Sell
-45
Closed -$772 – 1759
2025
Q1 		$772 Buy
45
+3
+7% +$67 ﹤0.01% 2082
2024
Q4 		$1.11K Buy
+42
New +$1.14K ﹤0.01% 2017

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's CLDX Position: Q2 2026 in Review

Amundi held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 9,351 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #1794.

Amundi first reported a position in CLDX in Q4 2024 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Amundi held 9,351 shares of Celldex Therapeutics worth $348K as of Q2 2026.
  • Amundi left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1794 holding.
  • Amundi first reported a position in Celldex Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.